PROLOR Biotech — 5th Diabetes Drug Discovery & Development Conference (April 2012)
14 slides from PROLOR Biotech's conference presentation, Apr 19, 2012
Slide 1: Long Acting Reversible PEGylated Oxyntomodulin - MOD-6030
Long Acting Reversible PEGylated Oxyntomodulin - MOD - 6030 Apr 2012 5th Diabetes Drug Discovery & Development Conference
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward - looking statements, including statements regarding the results of current studies and pre - clinical experiments and the effectiveness of PROLOR’s long - acting protein programs and are made pursuant to the safe harbour provisions of the Pri
Slide 3: PROLOR's Expected Product Pipeline
Indication Product Market Size Preclin. Ph I Ph II Ph III Growth Disorders hGH - CTP $3B Hemophilia Factor VIIa - CTP $1.3B 2 / week injection Factor IX - CTP $0.7B 1 /week injection Diabetes Type II & Obesity GLP1/Glucagon dual receptor agonist $2B 1/week injection PROLOR’s Expected Product Pipelin
Slide 4: Reversible PEGylation - Mechanism
4 Reversible PEGylation - Mechanism 4 PEG chain too large → lost activity • PEG chain hydrolyzes at controlled PK profile • Authentic drug released • Unique linkers, patent protected Native peptide - Fully Active + H 2 0 Physiological hydrolysis pH 7; 37 o C PEG chain PEG chain Hydrolyzed Linker Hyd
Slide 5: REV-PEG Technology Main Advantages
REV - PEG Technology Main Advantages: □ Long lasting fully active authentic peptide □ 1 st order hydrolysis reaction (slow, supporting predictable pharmacokinetic pattern) □ Dose reduction □ Technology applicable for all peptides and a wide range of small molecules. □ Allows development of long acti
Slide 6: Oxyntomodulin – Nature's Appetite Control Mechanism
REV - PEG Technology main advantages: 6 Oxyntomodulin – Nature’s Appetite Control Mechanism • Natural appetite suppressor • Oxyntomodulin is a dual GLP - 1 /Glucagon receptor agonist • Secreted by the digestive system following food intake and induces satiety in the brain • Crosses blood - brain bar
Slide 7: Long-Acting GLP-1/Glucagon Dual Receptor Agonist versus Native Oxyntomodulin
MOD - 6030 — Long - Acting GLP - 1/Glucagon Dual Receptor Agonist versus Native Oxyntomodulin: Previous 3 rd party oxyntomodulin studies: Animals (mice, rats): 2 injections per day Glycemic control Food intake reduced Weight loss observed Humans: 3 injections per day Weight Loss of 0.5 k
Slide 8: Feasibility Study in DIO Mice Model Study Design
Feasibility Study in DIO Mice Model Study Design 8 Day 2 weeks base line Injection 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Injection Injection Injection Injection OGTT (Day2) OGTT(Day 23 ) Glucose Insulin Cholesterol Body Composition Treatment (sc) Test Artic
Slide 9: Once Weekly Administration Significantly Reduces Body Weight in DIO Mice
Once Weekly Administration of MOD - 6030 Significantly Reduces Body Weight in DIO Mice 9 30 35 40 45 50 55 60 65 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Body weight (g) Day - 1.6% - 16.6% - 27.6 % Effect of MOD - 6030 (Hydrolyzed Linker),
Slide 10: Significant Advantages in Weight Reduction
MOD - 6030 Significant Advantages in Weight Reduction 10 Treatment Injection Frequency Dose per Injection Cumulative Dose in 30 Days Cumulative Weight Loss Day 30 (%) Cumulative Food Intake Reduction (%) Formulation Buffer 2x per Day -- -- 0.3% Gain -- OXM 2x per Day 6,000 nm 348,000 nm 16.6% Loss 1
Slide 11: Induces Glucose Tolerance in DIO Mice
MOD - 6030 Induces Glucose Tolerance in DIO Mice 11 RS712 Part 4: Effect of PEG40-EMCS-OXM, PEG30-EMCS-OXM, PEG40-FMS-OXM, PEG30-FMS-OXM, OXM, liraglutide and sibutramine on glucose tolerance (2g/kg po) in male C57BL/6J mice which exhibit diet-induced obesity Male C57BL/6J mice were from Charles Riv
Slide 12: Once Weekly Administration Improves Glycemic and Lipidic Profiles
Once Weekly Administration of MOD - 6030 Improves Glycemic and Lipidic Profiles 12 Terminal Glucose Terminal Cholesterol Terminal Insulin Terminal cholesterol A C E F G 0 50 100 150 200 250 PEG-SH (662 mg/kg) PEG30-EMCS-OXM (6000 nmol/kg) MOD-6030 (6000 nmol/kg) Vehicle (PBS bid) OXM (6000 nmol/kg b
Slide 13: Conclusions
Conclusions • RevPEG was shown to be safe and tolerable in different toxicological rodent animal models. • RevPEG enables elongation of peptides’ half lives while maintaining their potential to penetrate target tissues (e.g. penetrate the BBB). • MOD - 6030 demonstrates superior long acting properti
Slide 14: Thank You
Thank You PROLOR BIOTECH Protein .Longevity. Redefined PROLOR BIOTECH
PROLOR Biotech — 5th Diabetes Drug Discovery & Development Conference (April 2012) on 6ix